Caladrius Biosciences, Inc. (CLBS) Stock Analysis

Caladrius Biosciences, Inc. (CLBS) Healthcare & Pipeline Overview

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in cellular therapies for reversing disease and regenerating damaged tissue. Their pipeline targets unmet needs in critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease, positioning them within the competitive biotechnology landscape.

What Is the Investment Thesis for CLBS?

Caladrius Biosciences presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful progression of its clinical-stage assets, particularly HONEDRA, XOWNA, and CLBS201. Positive Phase II trial results for HONEDRA in critical limb ischemia could serve as a significant catalyst, given the SAKIGAKE designation and potential for expedited regulatory review in Japan. Similarly, advancement of XOWNA through Phase IIb trials for coronary microvascular dysfunction will be crucial. The company's small market capitalization reflects the inherent risks associated with clinical-stage biopharmaceutical companies, including clinical trial failures, regulatory hurdles, and financing challenges. Revenue generation is dependent on successful commercialization, which is several years away. Investors should carefully weigh the potential upside against the significant risks involved.

Based on FMP financials and quantitative analysis

CLBS Key Highlights

Caladrius Biosciences operates with a lean team of 27 employees, reflecting its focus on research and clinical development.

• The company's gross margin stands at 91.2%, indicating strong potential profitability upon successful commercialization of its therapies.
• The company's pipeline includes HONEDRA, a recipient of SAKIGAKE designation, which may lead to faster regulatory pathways.
• Caladrius Biosciences focuses on cellular therapies, a growing field with potential for regenerative medicine.
• The company's P/E ratio is -2.63, reflecting its current lack of profitability as a clinical-stage company.

Who Are CLBS's Competitors?

CLBS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CLBS's Key Strengths?

Proprietary cell therapy technologies.

• SAKIGAKE designation for HONEDRA.
• Clinical-stage pipeline targeting unmet medical needs.
• Experienced management team.

What Are CLBS's Weaknesses?

Limited financial resources.

• Dependence on clinical trial success.
• Lack of commercial infrastructure.
• High R&D costs.

What Could Drive CLBS Stock Higher?

Phase II clinical trial results for HONEDRA in critical limb ischemia.

• Phase IIb clinical trial results for XOWNA in coronary microvascular dysfunction.
• Enrollment and progress in clinical trials for CLBS201 in chronic kidney disease.
• Potential strategic partnerships or collaborations.
• Regulatory updates regarding SAKIGAKE designation for HONEDRA.

What Are the Key Risks for CLBS?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Clinical trial failures for HONEDRA, XOWNA, or CLBS201.
• Regulatory delays or rejections.
• Competition from other biotechnology companies.
• Dependence on securing additional financing.
• Patent challenges or intellectual property disputes.

What Are the Growth Opportunities for CLBS?

• Expansion of HONEDRA into New Markets: HONEDRA, currently in Phase II trials for critical limb ischemia and holding SAKIGAKE designation, presents a significant growth opportunity for Caladrius Biosciences. If clinical trials prove successful, expanding HONEDRA's availability beyond its initial target markets, particularly in regions with high prevalence of peripheral artery disease, could drive substantial revenue growth.
• Advancement of XOWNA for Coronary Microvascular Dysfunction (CMD): XOWNA, in Phase IIb trials for CMD, represents another key growth driver. CMD is an underdiagnosed and undertreated condition, creating a significant unmet medical need. Positive clinical trial results and subsequent regulatory approval could position XOWNA as a first-in-class therapy for CMD. The market for CMD treatments is expected to grow as diagnostic rates improve, providing a favorable environment for XOWNA's commercial success. The timeline for potential commercialization is dependent on the successful completion of Phase IIb trials and subsequent regulatory review.
• Development of CLBS201 for Chronic Kidney Disease (CKD): CLBS201, a CD34+ cell therapy for pre-dialysis CKD patients, offers a long-term growth opportunity. CKD is a growing global health problem, and new therapies are needed to slow disease progression and delay the need for dialysis. If CLBS201 demonstrates efficacy in clinical trials, it could capture a significant share of the CKD treatment market. The timeline for CLBS201's development is longer than HONEDRA and XOWNA, but the potential market size is substantial.
• Strategic Partnerships and Collaborations: Caladrius Biosciences can accelerate its growth by forming strategic partnerships with larger pharmaceutical companies. Collaborations can provide access to funding, expertise, and commercial infrastructure, enabling Caladrius to advance its pipeline more efficiently. Potential partnership opportunities include co-development agreements, licensing deals, and joint ventures. These partnerships could significantly de-risk the company's development programs and accelerate the commercialization of its therapies. The timing of such partnerships is uncertain, but they represent a key potential growth driver.
• Expansion into New Therapeutic Areas: While Caladrius is currently focused on critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease, the company could expand its pipeline into new therapeutic areas with unmet medical needs. This could involve developing cell-based therapies for other cardiovascular diseases, autoimmune disorders, or neurological conditions. Expanding into new therapeutic areas would diversify the company's risk profile and create new growth opportunities. The timeline for such expansion is dependent on the company's research and development efforts and its ability to identify promising new targets.

What Are CLBS's Competitive Advantages?

• Patented cell therapy technologies.
• SAKIGAKE designation for HONEDRA, providing regulatory advantages.
• Clinical trial data demonstrating safety and efficacy.
• Expertise in cell therapy development and manufacturing.

What Does CLBS Do?

Caladrius Biosciences, Inc., established in 1980 and headquartered in Basking Ridge, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing cellular therapies. Originally incorporated as NeoStem, Inc., the company rebranded to Caladrius Biosciences in June 2015, marking a strategic shift towards its current focus. The company's mission is to reverse disease progression and promote the regeneration of damaged tissue through innovative cell-based therapeutics. Caladrius's product pipeline includes HONEDRA (recipient of SAKIGAKE designation) for critical limb ischemia, currently in Phase II clinical trials. XOWNA, another key asset, is in Phase IIb clinical trials targeting coronary microvascular dysfunction. Additionally, CLBS201, a CD34+ cell therapy, is being developed for pre-dialysis patients with chronic kidney disease. These therapies represent Caladrius's commitment to addressing significant unmet medical needs in areas with limited treatment options. The company operates primarily in the United States, focusing on research, development, and clinical trials to advance its product candidates toward commercialization. Caladrius Biosciences aims to establish itself as a leader in the cellular therapy space by leveraging its scientific expertise and clinical development capabilities.

What Products and Services Does CLBS Offer?

• Develops cell therapies for reversing disease.
• Focuses on regenerating damaged tissue.
• Conducts Phase II clinical trials for HONEDRA to treat critical limb ischemia.
• Conducts Phase IIb clinical trials for XOWNA to treat coronary microvascular dysfunction.
• Develops CLBS201, a CD34+ cell therapy for pre-dialysis patients with chronic kidney disease.
• Engages in research and development of cell-based therapeutics.

How Does CLBS Make Money?

• Develops and patents cell therapy technologies.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval for its therapies.
• Aims to commercialize its therapies through direct sales or partnerships.

What Industry Does CLBS Operate In?

Caladrius Biosciences operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy clinical trials, and stringent regulatory oversight. The cellular therapy market is experiencing significant growth, driven by advancements in regenerative medicine and the increasing prevalence of chronic diseases. Key industry trends include the development of personalized therapies, the use of gene editing technologies, and the growing importance of strategic partnerships. Caladrius competes with other biotechnology companies developing cell-based therapies for various indications. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and establish commercial partnerships.

Who Are CLBS's Key Customers?

• Patients with critical limb ischemia.
• Patients with coronary microvascular dysfunction.
• Pre-dialysis patients with chronic kidney disease.
• Healthcare providers who treat these patients.

Company Profile

Caladrius Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Basking Ridge, US. The company is led by CEO David Mazzo. CLBS has traded publicly since 1995.

Caladrius Biosciences, Inc. (CLBS) Valuation Context

Valued at $3.35M, CLBS is classified as a micro-cap stock.

Key Financial Metrics

Its free cash flow yield is -44.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -53.4%, the inverse of the P/E and a quick read on earnings relative to price.

Caladrius Biosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

CLBS Financials

CLBS Latest News

Common Questions About CLBS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources